Aethlon Medical to Showcase Hemopurifier at Emerging Growth Conference
Event summary
- Aethlon Medical (Nasdaq: AEMD) will present at the Emerging Growth Conference on February 25, 2026, from 12:30-1:00 PM ET.
- CEO and CFO Jim Frakes will lead a fireside chat and Q&A session.
- The Hemopurifier, Aethlon's investigational device, targets cancer and infectious diseases.
- The device holds FDA Breakthrough Device Designation for advanced cancer and life-threatening viruses.
The big picture
Aethlon's participation in the Emerging Growth Conference underscores its push to engage institutional investors and analysts amid a critical phase of clinical development. The Hemopurifier's FDA Breakthrough Device Designation positions it as a potential disruptor in oncology and infectious disease treatment, but its success hinges on demonstrating efficacy in ongoing trials. The company's ability to secure additional financing and maintain Nasdaq compliance will be key to sustaining its growth trajectory.
What we're watching
- Clinical Progress
- The pace at which Aethlon advances its oncology and infectious disease trials will determine the Hemopurifier's commercial viability.
- Regulatory Pathway
- Whether the FDA Breakthrough Device Designation accelerates approval timelines for the Hemopurifier.
- Market Positioning
- How Aethlon differentiates itself in the competitive landscape of cancer and infectious disease therapies.
Related topics